Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Proteros and Priaxon Announce Lead Discovery Collaboration on Protein-Protein Interaction Targets

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Proteros biostructures GmbH announced they entered into a Lead Discovery Collaboration with Priaxon AG to jointly develop lead compounds for high value protein-protein interaction (PPI) drug targets.

The combination of Proteros’ structure guided discovery with Priaxon’s PPI-directed drug discovery platforms will be focused on the identification of novel small molecule modulators for PPI targets. As part of this collaboration, Proteros will apply its integrated Lead Discovery expertise and technologies in the field of structural biology, biophysics and screening. Priaxon will apply its proprietary drug discovery platform  Priaxplore®, which combines a proprietary PPI focused chemical space with special tailor made chemoinformatic methods for the identification of potential PPI modulators.

“The combination of Proteros’ strength in structural biology and biophysics with the Priaxon’s PPI focused drug discovery platform Priaxplore® forms an excellent basis to make PPI targets of high interest addressable by small molecule modulators" said Dr. Juergen Kolb, CEO of Priaxon.

Dr. Torsten Neuefeind, CEO of Proteros, stated: "We are very pleased to have formed this relationship with Priaxon. Both companies have complementary platforms as well as an established track-record. PPIs are a big challenge in drug discovery and the use of structural information, computational chemistry and Priaxons’ validated chemistry approach allows us to respond to the industry demand for such targets in a unique manner”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Proteros, Merck Sharp & Dohme Corp. Collaborate
Proteros to receive upfront and research funding plus milestone payments of up to $126 million plus royalties.
Wednesday, October 07, 2015
Proteros Appoints Dr. Torsten Hoffmann as Chief Scientific Officer
Dr. Hoffmann will support the further growth of the Company’s Discovery business.
Tuesday, June 30, 2015
Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration
Company to discover potent and selective small molecule inhibitor series against a novel protein target.
Tuesday, May 19, 2015
Proteros Enters into a Collaboration with Bayer
Collaboration to develop new cardiovascular drug compounds for an integral membrane protein.
Saturday, January 10, 2015
Proteros Announces Changes in Management Team
The changes see a new Chief Financial Officer, and a promotion to Chief Operating Officer.
Monday, May 12, 2014
Proteros Elects New Supervisory Board Member
Shareholders confirmed the appointment of Prof. Eric-Paul Pâques as a new member of the Supervisory Board.
Thursday, February 20, 2014
Rodin Therapeutics Applies Insights of Epigenetics to Neurological Disorders
Founded by Atlas Venture and Proteros biostructures.
Monday, July 01, 2013
Proteros and Eisai Announces Successful Completion of Collaboration
Proteros and Eisai achieve target in lead discovery project, delivering kinetically optimized lead compounds.
Tuesday, May 07, 2013
Proteros and Eisai Achieve Target in Lead Discovery Project
Companies delivering kinetically optimized lead compounds.
Tuesday, May 07, 2013
UCB and Proteros Expand Collaboration
Expansion of the ongoing structural biology collaboration will include additional therapeutic areas.
Monday, September 17, 2012
Proteros Announces Successful Close of Financing Round
Largest-ever financing allows for expansion of drug discovery capabilities.
Tuesday, August 07, 2012
Proteros and Eisai Co., Ltd Enter into Integrated Lead Discovery Collaboration
Companies partner to identify small molecule inhibitors.
Monday, April 16, 2012
Proteros Appoints Dr Klaus Hinterding
Dr Klaus Hinterding, formerly at Hoffmann-La Roche Ltd, joins Proteros biostructures GmbH as Chief Scientific Officer and member of the management board.
Monday, February 13, 2012
Proteros Obtains CIR Accreditation
Accreditation allows eligible clients to receive 30% of their R&D costs in tax credits.
Wednesday, January 25, 2012
Rigel and Proteros Renew X-ray Protein Crystallography Collaboration
Proteros will provide X-ray structure analysis of protein-compound complexes for specific targets to support Rigel’s discovery efforts.
Thursday, August 04, 2011
Scientific News
Breaking Through the Barriers to Lab Innovation
Here we examine the drivers behind the move for greater innovation, the challenges and current trends in laboratory informatics, and the tools that can be used to break these barriers.
Education and Expense: The Barriers to Mass Spectrometry in Clinical Laboratories?
Here we examine the perceived barriers to mass spec in clinical laboratories and explore the possible drivers behind the recent shift in uptake of the technology in clinical settings.
Fruit Fly Pheromone Flags Great Real Estate for Starting a Family
Finding could aid efforts to control mosquito-borne diseases like malaria by manipulating odorants
Gene Editing Could Enable Pig-To-Human Organ Transplant
The largest number of simultaneous gene edits ever accomplished in the genome could help bridge the gap between organ transplant scarcity and the countless patients who need them.
Antioxidants Cause Malignant Melanoma to Metastasize Faster
Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Adult High Blood Pressure Risk Identifiable in Childhood
Groups of people at risk of having high blood pressure and other related health issues by age 38 can be identified in childhood, new University of Otago research suggests.
Analyzing Protein Structures in Their Native Environment
Enhanced-sensitivity NMR could reveal new clues to how proteins fold.
Supercoiled DNA is Far More Dynamic Than the “Watson-Crick” Double Helix
Researchers have imaged in unprecedented detail the three-dimensional structure of supercoiled DNA, revealing that its shape is much more dynamic than the well-known double helix.
Mini-kidneys Successfully Grown from Stem Cells
Researchers from Murdoch Childrens Research Institute have perfected a method of turning stem cells into mini-kidneys for use in drug screening, disease modelling and cell therapy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos